B*******y
发帖数: 766 | 1 sleepyy老师以后可得多关照关照师弟我啊，哈哈哈哈
new |
|
c****e
发帖数: 14 | 2 朋友应聘了这个公司， 但不知道这公司在美国排名地位如何？ 有知道的同志可否给科
普一下？ 谢谢了！ |
|
F****s
发帖数: 52 | 3 现在大药厂基本都裁过人了,有没有人知道SGP最近会不会裁? |
|
b**u
发帖数: 2761 | 4 不错啊，你朋友不是制药这行的进这个公司是个非常好的开始了。排名好像应该是前二
三十吧。 |
|
|
|
o***n
发帖数: 82 | 7 $1500?
aventis 是 $1500，好像schering-plough也差不多 |
|
b**u
发帖数: 2761 | 8 Schering Plough应该也是Senior Scientist吧。 |
|
s********7
发帖数: 3 | 9 Roche, Principal Scientist
Novartis, Senior Scientist,
Schering plough, Senior Scientist |
|
v******V
发帖数: 314 | 10 ☆─────────────────────────────────────☆
Lilycat (婆猫) 于 (Sun Nov 18 23:59:31 2007) 提到:
Biogen, Scientist I
BMS, Research Investigator I
Boehringer ingelheim, Senior Scientist
GSK, Principal Scientist
Affymax, Staff Scientist
Abbott, Senior Scientist
Covance, Staff Scientist
☆─────────────────────────────────────☆
bleu (Crystal Jade 翡翠小厨) 于 (Mon Nov 19 11:08:50 2007) 提到:
Schering Plough应该也是Senior Scientist吧。
☆─────────────────────────────────────☆
mklb (wisher_washer) 于 (Mon Nov 19 1 |
|
c**p
发帖数: 1443 | 11 also no related report on Shering-Plough ba. |
|
s****y
发帖数: 3437 | 12 我想请问一下大家都是做完on-site多久有消息，他们有给据信的习惯吗？谢谢 |
|
r***o
发帖数: 162 | 13 I thought they are laying off people right now. |
|
f*******y
发帖数: 24 | 14 Normally two weeks. They are downsizing right now due to the buy out of
organon bioscience. |
|
|
|
E***n
发帖数: 308 | 17 it is getting worse, stock down 25% one day. |
|
|
c***a
发帖数: 38 | 19 Which department are you interviewing? Most of their reorganization is for
the Europe part. The clinical department is still hiring. Good luck! |
|
N***n
发帖数: 660 | 20 这就是所谓的庄家出货前雇用的黑嘴了
今天再看看这二位的股票
ahead
cholesterol
Amex |
|
c********g
发帖数: 1106 | 21 haha, 这消息我喜欢，爬得高摔得重。Vytorin对S-P 影响严重么？ |
|
|
s*******n
发帖数: 11 | 23 SP完了.
Merck是最伤人心的.作为以最纯正精良的药学研究而自豪的大药厂混到今天这种地步,
简直就是谱写了行业衰落墓志铭. |
|
|
R*j
发帖数: 248 | 25 大药厂一般集中投资在发病率，死亡率最高的几个方面：心血管，糖尿病，癌症，感染
。。。。。。多年的研究已经产生了很多有效的药物。这部分药物现在开始变为非专利
药了。如何研制出比现有药物更有效的新药是所有大药厂面临的非常难超越的难题。
Scios （part of JNJ) 做了个治疗acute heart failure的nesiritide，但是马上被人
诟病：可能效果和硝酸甘油差不多。
Novartis 搞了个降血压的aliskiren,马上就有人怀疑其相对于血管紧张素"普利"类的
优越性．
ahead
cholesterol
Amex |
|
|
l*****k
发帖数: 587 | 27 I feel biologics is the future... it is all about specificity, small
molecules can't be that specific in many complicated diseases. |
|
R*s
发帖数: 2041 | 28 specificity is a double-blade sword anyway.
感染
专利
被人
类的 |
|
l*****k
发帖数: 587 | 29 yeah... true, but I think once you can specifically target
things, the treatment can get more accurate, then a
cocktail method of multiple specific drug may start
to emerge. |
|
r***o
发帖数: 162 | 30 I hope you are not in pharma yet,
what you said scares me. :-) |
|
l*****k
发帖数: 587 | 31 in pharma :) don't get what you mean by what you said.
I was just trying to say biologics are very specific and
treatment based on specific targets is more accuate, less
toxicity, etc. I am sure there are other issues with
biologics compared with small molecule. |
|
B*******y
发帖数: 766 | 32 好像Wuxi里边有一个号称在Schering Plough作了10年“首席”科学家的 |
|
r***o
发帖数: 162 | 33 The sales of Humira will go down with the approval of golimumab.
Gilead is a good company, but none of its products will make Gilead next
Amgen.
For viral treatments, HCV is a pot of gold now. Vertex and Schering-plough
took the lead. |
|
e*****i
发帖数: 993 | 34 我也不了解公司的情况，也不了解股票，根本猜不到。
那我就来吓猜两个吧：gsk, schering-plough？ |
|
N***n
发帖数: 660 | 35 Schering-plough一个Recruitment Manager说他们想找一个MS pay 77k in boston，这
种一般得多少年经验？ |
|
|
s**********r
发帖数: 330 | 37 Hard to tell which company is 更稳定／前景更好, but I would go to Norvatis.
Do you have both offers in your hand? If so you can compare the money,
benefits and vacation stuff then you will have your answer. |
|
s*****i
发帖数: 62 | 38 look novartis is better positioned.
Seems from their stock price. |
|
s**********r
发帖数: 330 | 39 Why did you make such statements? Quite a few colleagues in my department
joined from CRO's. In the meantime some are leaving for CRO's. I just don'
t see boundaries between those two orgs. |
|
s*****i
发帖数: 62 | 40 Dancing Daxia.
How do you view the pharm in general? any insight on which is safer
relatively?
Pfizer, Merck, Novartis, Roche? etc
Thanks. |
|
E***n
发帖数: 308 | 41 it holds in general IMHO.
10 |
|
m*p
发帖数: 212 | 42 there are a few tox people in my company coming from CRO, but I haven't
seen a med chem scientist from CRO, most med chem new hires are from fresh
postdoc or big pharma.
10 |
|
y********n
发帖数: 269 | 43 我一朋友在这边一大制药公司，现聘到另一家大公司在中国的部门了。做team Leader
条件不错. |
|
R*s
发帖数: 2041 | 44 that's true, but does that demonstrating anything aganist 6ftunder's
comments?
10
department |
|
s*****y
发帖数: 4595 | 45 i agree changing from CRO to big pharm is not as easy as the other way
around, but in the past 3 or 4 years i know at least three PhD level organic
chemists jumping from my current company to big pharm. they are all chinese
, not sure about non-chinese
1 BMS (med chem)
1 SP (med chem)
1 Roche (chem process) |
|
s*****y
发帖数: 4595 | 46 i heard med chem (especially entry level) in industry is not that much
different from academia so fresh PhD/postdoc from good groups tend to have
better chances.
but when it comes to some division when experience counts more (say,
chemical development and process), fresh PhDs will have less change than
experienced chemists from CRO/small pharm |
|
l****6
发帖数: 18 | 47 我是猎头，我们在招有海外工作背景的化学人才，也是医药上市公司，在上海，不知道
您会考虑吗？
有意向可以发简历至J***[email protected] |
|
|
s*****l
发帖数: 1844 | 49 Will cut 15% of combined work force, but mainly outside the USA...
Holy cow. More people will lose jobs.
1 |
|
|
